The first liver-directed therapy for the treatment of adult with metastatic uveal melanoma is now FDA approved.
Publications
MRV Newsletter – October 2023
>> MRV Newsletter October 2023 (Updated: 1 November 2023, Please download again)
Read More European Medicines Agency recommends Opdivo for treatment of earlier melanoma stages
Opdivo (nivolumab) is a programmed cell death protein 1 (PD-1) inhibitor.
Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of nivolumab (Opdivo) monotherapy for the adjuvant treatment of patients at least 12 years of age with completely resected stage IIB or IIC melanoma.